AlzeCure Pharma AB has received the full USD 10 million upfront payment from Eli Lilly under a collaboration and licensing agreement covering its Alzheimer's disease programme Alzstatin, including the investigational drug candidate ACD680.

The payment follows the agreement between AlzeCure and Eli Lilly signed on June 9, 2026. With the upfront payment received and customary closing conditions fulfilled, including approval by Swedish authorities under foreign direct investment screening regulations, the initial transaction has now been completed.

The USD 10 million payment has been received in full and does not involve dilution for AlzeCure shareholders. In addition to the upfront consideration, the agreement provides for development and commercial milestone payments as well as royalties in the mid-single-digit percentage range on future product sales.

The total value of the agreement, excluding royalty payments, could exceed USD 1 billion.

Under the agreement, Eli Lilly will assume global rights to Alzstatin and responsibility for the continued clinical development and potential commercialisation of ACD680.

Martin Jönsson, CEO of AlzeCure Pharma, said Lilly's selection of the Alzstatin platform validates the company's research conducted over several years and that the upfront payment significantly strengthens its financial position.

Jönsson added that AlzeCure will continue its work in Alzheimer's disease through both the Alzstatin and NeuroRestore programmes, while increasing investment in its pain research portfolio, led by TrkA-NAM and ACD440.

ACD680 is a gamma-secretase modulator being developed as part of the Alzstatin programme. The candidate is designed to reduce the production of amyloid-beta 42 (Aβ42), a form of amyloid-beta associated with the formation of amyloid plaques in the brains of people with Alzheimer's disease.

The drug candidate is also designed to increase the production of shorter forms of amyloid-beta, Aβ37 and Aβ38. These shorter peptides may reduce the aggregation of Aβ42 and potentially limit the formation of harmful amyloid plaques.

The completion of the transaction follows the fulfilment of customary closing requirements, including regulatory approval from Swedish authorities under rules governing the screening of foreign investments and acquisitions.

The deal provides Eli Lilly with global rights to the Alzstatin programme while giving AlzeCure additional financial resources to advance its broader pipeline of therapies targeting Alzheimer's disease and pain.